Einsatz von Doxycyclin zur Behandlung der kardialen Amyloidose

• Antragsteller: Professor Dr. Stefan Schönland
• Fachliche Zuordnung: Hämatologie, Onkologie
• Förderung: Förderung von 2017 bis 2022
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 342064388

• Erstellungsjahr: 2022

Zusammenfassung der Projektergebnisse

The current clinical trial was started despite many difficulties related to the regulatory approvals from different European countries. The longer time for the complete approval and the impact of COVID-19 pandemic negatively influenced the recruitment rate and the trial conduct. As previously stated, the negative results from a clinical trial exploring the use of doxycycline in AL amyloidosis and the low recruitment rate, led to the anticipated closure of the study.